2025
PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma
Guo M, Chen S, Sun J, Xu R, Qi Z, Li J, Zhou L, Fang Y, Liu T, Xia J. PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma. Advanced Science 2025, e04372. PMID: 40405713, DOI: 10.1002/advs.202504372.Peer-Reviewed Original ResearchNrf2-dependent transcriptionHepatocellular carcinomaKinase-independent mannerProgrammed cell deathKelch domain of Kelch-like ECH-associated protein 1Sensitizes HCC cells to sorafenibHepatocellular carcinoma tumorigenesisIron-dependent formInduced sorafenib resistanceKelch domainPIP5K1AKelch-like ECH-associated protein 1Inhibit HCC growthCells to sorafenibECH-associated protein 1Cell deathSorafenib-induced ferroptosisEfficacy of sorafenibHepatocellular carcinoma patientsFerroptosis resistanceCancer-related mortalityUbiquitination degradationFerroptosis inducersProtein 1Stabilize Nrf2Mitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway
Gao Y, Peng Y, Zhou Y, Zhu J, Fu S, Chen Y, Cai C, Han Y, Shen H, Zeng S, Mao L, Xiao Z. Mitochondrial gene SLC25A24 regulated anti-tumor immunity and inhibited the proliferation and metastasis of colorectal cancer by PKG1-dependent cGMP/PKG1 pathway. International Immunopharmacology 2025, 157: 114664. PMID: 40334626, DOI: 10.1016/j.intimp.2025.114664.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAnti-tumor immunityColorectal cancerResponse to immune checkpoint inhibitorsAssociated with worse overall survivalKaplan-Meier survival analysisProgression-free survivalTumor immune regulationMetastasis of colorectal cancerMitochondrial solute carriersMicrosatellite instabilityColorectal cancer cell linesColorectal cancer patientsCancer-related mortalityProliferation-related markersCheckpoint inhibitorsColorectal cancer progressionOverall survivalImmune infiltrationPotential therapeutic targetPrognostic markerUnfavorable prognosisColorectal cancer tissuesImmune regulationClinical cohortPLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity.
Dominguez-Vigil I, Banik K, Baro M, Contessa J, Hayman T. PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity. Molecular Cancer Therapeutics 2025, of1-of12. PMID: 40296663, DOI: 10.1158/1535-7163.mct-24-0978.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerCFI-400945Mitotic catastropheNon-small cell lung cancer radiosensitizationRadiosensitivity of NSCLC cell linesCentrosome amplificationRadiation-induced tumor growth delayPLK4 inhibitionCell deathCurative-intent chemoradiationIncreased G2/M cell cycle arrestPolo-like kinase 4Subtype of lung cancerCell lung cancerIncreased centrosome amplificationCancer-related mortalityG2/M cell cycle arrestNSCLC cell linesCell cycle phase distributionClinical trial evaluationTargeting PLK4NSCLC in vitroCell cycle arrestPotential therapeutic targetTop advances of the year: Small cell lung cancer
Shields M, Chiang A, Byers L. Top advances of the year: Small cell lung cancer. Cancer 2025, 131: e35770. PMID: 40040254, DOI: 10.1002/cncr.35770.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerExtensive-stage small cell lung cancerCell lung cancerLung cancerLimited-stage small cell lung cancerFrequency of disease relapseTiming of immunotherapyCancer-related mortalityLong-term survivalAntibody-drug conjugatesNeuroendocrine subtypeDisease relapseAggressive biologyMetastatic spreadInferior outcomesImproved survivalImmunotherapyTherapeutic breakthroughConsolidation treatmentCancerPrecision medicineBiomarker selectionSurvivalLurbinectedinForward-thinking approachExploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma
Yang L, Pham K, Xi Y, Wu Q, Liu D, Robertson K, Liu C. Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma. PLOS ONE 2025, 20: e0317401. PMID: 39841705, PMCID: PMC11753693, DOI: 10.1371/journal.pone.0317401.Peer-Reviewed Original ResearchConceptsGlypican-3Hepatocellular carcinomaCAR-NKNatural killerCell linesCAR-NK therapyCAR-NK cellsTreatment of hepatocellular carcinomaNK cell lineAnti-tumor effectsCancer-related mortalitySuppressed tumor growthPrimary liver cancerInfluence therapeutic outcomesCells in vitroHepatocellular carcinoma treatmentHepG2 cells in vitroNK92MI cellsImmunotherapy strategiesNSG miceImmunotherapy targetOncofetal glycoproteinTherapy resistanceImprove patient outcomesPoor prognosis
2024
Vaping and tumor metastasis: current insights and progress
Xi Y, Yang L, Burtness B, Wang H. Vaping and tumor metastasis: current insights and progress. Cancer And Metastasis Reviews 2024, 44: 4. PMID: 39581913, PMCID: PMC11792352, DOI: 10.1007/s10555-024-10221-7.Peer-Reviewed Original ResearchConceptsEpithelial-mesenchymal transitionE-cigsPromote metastasisTumor metastasisCancer metastasisCause of cancer-related mortalityEffects of e-cigsE-cig exposureDormant tumor cellsPrimary cause of cancer-related mortalityPre-metastatic nicheImpact of e-cigarettesTumor cell spreadCancer-related mortalityTraditional cigarette smokingE-cig useLong-term health implicationsIncreased cell migratoryPromote lymphangiogenesisTumor cellsTumor progressionSignificant epigenetic changesMetastatic potentialMetastasisTumorElectrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review
Barbieri P, Posa A, Lancellotta V, Madoff D, Maresca A, Cornacchione P, Tagliaferri L, Iezzi R. Electrochemotherapy in the Locoregional Treatment of Metastatic Colorectal Liver Metastases: A Systematic Review. Current Oncology 2024, 31: 7403-7413. PMID: 39590176, PMCID: PMC11592455, DOI: 10.3390/curroncol31110546.Peer-Reviewed Original ResearchConceptsCRC liver metastasesLiver metastasesColorectal cancerComplete responseOverall survivalProgressive diseaseInclusion criteriaResection of CRC liver metastasesTreatment of CRC liver metastasisColorectal cancer liver metastasesSystematic searches of PubMedFrequent liver metastasesMedian overall survivalSecondary liver cancerFollow-up durationColorectal Liver MetastasesMultiple risk factorsCancer-related mortalitySearch of PubMedECT-related complicationsEvidence qualityLocoregional treatmentSurgical resectionIdentified articlesGRADE approach
2022
Knowledge, attitudes and practices concerning breast cancer, cervical cancer and screening among healthcare professionals and students in Mogadishu, Somalia: a cross-sectional study
Walz L, Mohamed D, Haibah A, Harle N, Al-Ali S, Moussa A, Alawa J, Awale M, Khoshnood K. Knowledge, attitudes and practices concerning breast cancer, cervical cancer and screening among healthcare professionals and students in Mogadishu, Somalia: a cross-sectional study. Ecancermedicalscience 2022, 16: 1455. PMID: 36405949, PMCID: PMC9666280, DOI: 10.3332/ecancer.2022.1455.Peer-Reviewed Original ResearchCervical cancerChronic care managementBreast cancerIncidence rateHealthcare professionalsHighest cancer-related mortalityBC incidence ratesBC mortality ratesHPV vaccine availabilityHuman papillomavirus vaccineCancer-related mortalityCross-sectional studyCross-sectional questionnaireLack of evidencePapillomavirus vaccinePatient refusalCancer screeningProvider knowledgeHealthcare workersVaccine availabilityMortality rateCare managementHigh mortalityVaccine accessCancerEvaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets
Alnoumas L, van den Driest L, Apczynski Z, Lannigan A, Johnson CH, Rattray NJW, Rattray Z. Evaluation of the role of KPNA2 mutations in breast cancer prognosis using bioinformatics datasets. BMC Cancer 2022, 22: 874. PMID: 35948941, PMCID: PMC9364282, DOI: 10.1186/s12885-022-09969-4.Peer-Reviewed Original ResearchConceptsBreast cancer prognosisBreast cancerCancer prognosisFemale cancer-related mortalityPoor patient survival outcomePrecision medicine-based approachKPNA2 overexpressionNovel chemotherapy agentsCancer-related mortalityPatient survival outcomesPoor patient prognosisAggressive tumor phenotypePatient agePrognostic rolePatient survivalSurvival outcomesPatient prognosisLeading causeChemotherapy agentsClinical dataCancer casesClinicopathologic parametersPatient stratificationActionable targetsChemotherapy resistanceDevelopment of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer
van den Driest L, Johnson CH, Rattray NJW, Rattray Z. Development of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer. Alternatives To Laboratory Animals 2022, 50: 282-292. PMID: 35765262, DOI: 10.1177/02611929221107546.Peer-Reviewed Original ResearchConceptsColorectal cancerBioinformatics toolsExpression patternsKirsten rat sarcoma viral oncogene homologueNext-generation sequencing technologiesDifferential expression patternsCancer-related mortalityGenetic alterationsAdenomatous polyposis coliEffector proteinsMutational driversPrognostic significancePrognostic valueSequencing technologiesBioinformatics pipelinePatient prognosisGenetic dataB-RafColorectal tumorsNovel biomarkersColon cancerTherapeutic outcomesFrequency of mutationsAnatomical locationOncogene homologue
2021
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis
Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. European Heart Journal 2021, 43: 300-312. PMID: 34791123, PMCID: PMC8914878, DOI: 10.1093/eurheartj/ehab745.Peer-Reviewed Original ResearchConceptsNew-onset atrial fibrillationBreast cancer patientsBreast cancer diagnosisAtrial fibrillationCancer patientsBreast cancer stageRisk factorsBreast cancerCardiovascular mortalityCancer stageCancer diagnosisAF incidenceBreast cancer-related mortalityDevelopment of AFCox proportional hazards modelNew primary diagnosisOnset atrial fibrillationRisk survival statisticsSEER-Medicare analysisCardiovascular risk factorsEnd Results-MedicarePrevalent atrial fibrillationKaplan-Meier methodUnited States cohortCancer-related mortalityImpact of the Affordable Care Act on Colorectal Cancer Incidence and Mortality
Lee C, Kushi LH, Reed ME, Eldridge EH, Lee JK, Zhang J, Spiegelman D. Impact of the Affordable Care Act on Colorectal Cancer Incidence and Mortality. American Journal Of Preventive Medicine 2021, 62: 387-394. PMID: 34763959, PMCID: PMC8863627, DOI: 10.1016/j.amepre.2021.08.025.Peer-Reviewed Original ResearchConceptsColorectal cancer-related mortalityColorectal cancer incidenceCancer-related mortalityColorectal cancer outcomesAffordable Care ActCancer incidenceColorectal cancerCancer outcomesCare ActKaiser Permanente Northern California membersHealth plansColorectal cancer screeningInterrupted time series designRace/ethnicityCancer screeningCalifornia membersPreventive servicesPrivate health insurancePocket costsMortalityTime series designIncidenceCost sharingCancerComparison group
2020
Novel Approaches to Screening for Breast Cancer
Mann R, Hooley R, Barr R, Moy L. Novel Approaches to Screening for Breast Cancer. Radiology 2020, 297: 200172. PMID: 32897163, DOI: 10.1148/radiol.2020200172.Peer-Reviewed Original ResearchConceptsBreast cancer-related mortalityBreast cancer screeningCancer screeningMolecular breast imagingCancer-related mortalityScreening modalitiesBreast imagingDigital breast tomosynthesisAggressive treatmentScreening strategiesFalse-positive rateBreast cancerSpectral mammographyLiquid biopsyBreath testScreening testBreastBreast tomosynthesisScreeningMammographyNovel approachesSubtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma
Robinson MH, Vasquez J, Kaushal A, MacDonald TJ, Vega J, Schniederjan M, Dhodapkar K. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Journal For ImmunoTherapy Of Cancer 2020, 8: e001066. PMID: 32788236, PMCID: PMC7422651, DOI: 10.1136/jitc-2020-001066.Peer-Reviewed Original ResearchConceptsT cell infiltrationHigh-grade gliomasT-cell densityLow-grade tumorsT cellsGlial tumorsTissue-resident memory T cellsTumor-resident T cellsPediatric gliomasTumor-infiltrating T cellsMemory T cellsCancer-related mortalityPediatric glial tumorsSingle-cell mass cytometryExpression of SOX2Stem cell markersImmune controlImmune therapyRecurrent tumorsImmune cellsImmunofluorescence immunohistochemistryPleomorphic xanthoastrocytomaBrain tumorsImmune architectureAdult gliomasEndoscopic ultrasound (EUS) and the management of pancreatic cancer
Yousaf MN, Chaudhary FS, Ehsan A, Suarez AL, Muniraj T, Jamidar P, Aslanian HR, Farrell JJ. Endoscopic ultrasound (EUS) and the management of pancreatic cancer. BMJ Open Gastroenterology 2020, 7: e000408. PMID: 32414753, PMCID: PMC7232396, DOI: 10.1136/bmjgast-2020-000408.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Pancreatic DuctalCholangiopancreatography, Endoscopic RetrogradeEarly DiagnosisEndosonographyFemaleGastroenterologyHumansInterdisciplinary CommunicationMaleMedical OncologyPancreatic NeoplasmsPatient Care ManagementPrevalenceRadiologyRandomized Controlled Trials as TopicSensitivity and SpecificityStentsSurgical OncologyConceptsManagement of patientsPancreatic cancerEndoscopic ultrasoundIdentification of patientsCancer-related mortalityPancreatic ductal adenocarcinomaSurgical candidatesMedical oncologyPancreatic malignancyDuctal adenocarcinomaRadiological imagingTherapeutic roleSurgical oncologyDiagnostic evaluationEarly diagnosisMultidisciplinary involvementInterventional endoscopyCancerPatientsWestern countriesOncologyManagementAdenocarcinomaMalignancyEndoscopy
2018
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). Journal For ImmunoTherapy Of Cancer 2018, 6: 75. PMID: 30012210, PMCID: PMC6048854, DOI: 10.1186/s40425-018-0382-2.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerCheckpoint inhibitorsLung cancerDurable responsesConsensus statementStage III non-small cell lung cancerAdvanced non-small cell lung cancerCancer consensus statementSequencing of therapySecond-line settingAppropriate patient selectionOnly treatment optionAdverse event managementCancer-related mortalityImmunotherapy of cancerEvidence-based recommendationsNew treatment approachesStrength of evidenceAdvanced diseasePatient selectionTargetable mutationsTreatment optionsCancer immunotherapyScreening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community
Su C, Bhargava A, Shah C, Halmos B, Gucalp R, Packer S, Ohri N, Haramati L, Perez-Soler R, Cheng H. Screening Patterns and Mortality Differences in Patients With Lung Cancer at an Urban Underserved Community. Clinical Lung Cancer 2018, 19: e767-e773. PMID: 29937386, DOI: 10.1016/j.cllc.2018.05.019.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedCarcinoma, Squamous CellCombined Modality TherapyDecision Support TechniquesEarly Detection of CancerFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMedically Underserved AreaMiddle AgedPrognosisRetrospective StudiesSmall Cell Lung CarcinomaSurvival RateTomography, X-Ray ComputedUrban PopulationConceptsUnited States Preventative Services Task Force guidelinesPrimary lung cancerTask Force guidelinesLung cancerScreening TrialMortality differencesPrimary care provider statusScreen-detected lung cancersNational Lung Screening TrialLung cancer-related mortalityLung Cancer Screening TrialActive smoking statusTime of diagnosisCancer Screening TrialCancer-related mortalityUnderserved communitiesUrban underserved communitiesLCS eligibilityCause mortalityPatient characteristicsProspective trialCurative treatmentSmoking statusSurgical managementCox regressionChapter 6 Management of Advanced Non–Small Cell Lung Cancer Noncurative Intent Treatment
Xia B, Herbst R. Chapter 6 Management of Advanced Non–Small Cell Lung Cancer Noncurative Intent Treatment. 2018, 99-115. DOI: 10.1016/b978-0-323-48565-4.00006-0.Peer-Reviewed Original ResearchNon-small cell lung cancerPD-L1 expressionPlatinum-based chemotherapyTreatment optionsLung cancerFirst-line systemic treatment optionMolecular alterationsSecond-line settingSystemic treatment optionsTime of diagnosisMain treatment optionCell lung cancerCancer-related mortalityBiomarkers of responseEfficacy of treatmentAbstract Lung cancerAdenocarcinoma histologyIntent treatmentMetastatic diseaseMost patientsClinical outcomesNoninvasive testingClinical trialsNovel therapiesTreatment strategies
2017
Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck
Bhatia A, Burtness B. Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck. Cancers 2017, 9: 113. PMID: 28858212, PMCID: PMC5615328, DOI: 10.3390/cancers9090113.Peer-Reviewed Original ResearchNeck cancerSecond primary tumorsExtensive clinical researchCancer-related mortalityNovel molecular targetsWhole-exome sequencingBiologic agentsOral leukoplakiaInvasive cancerPrimary tumorClinical trialsPrecursor lesionsNovel molecular pathwaysPrimary headMucosal fieldTumor specimensNeck regionCare optionsClinical researchCancerDriver mutationsExome sequencingMolecular targetsGenetic mutationsMolecular pathwaysSpectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients
Couto PP, Bastos-Rodrigues L, Schayek H, Melo FM, Lisboa RGC, Miranda DM, Vilhena A, Bale AE, Friedman E, De Marco L. Spectrum of germline mutations in smokers and non-smokers in Brazilian non-small-cell lung cancer (NSCLC) patients. Carcinogenesis 2017, 38: 1112-1118. PMID: 28968711, DOI: 10.1093/carcin/bgx089.Peer-Reviewed Original ResearchConceptsCell lung cancer patientsLung cancer patientsLung cancerSmoking statusCancer patientsWhole-exome sequencingGermline mutationsTP53 mutationsTP53 germline mutationsCell lung cancerCancer-related mortalityDistinct pathogenic mutationsMajor risk factorTumor-derived DNAMultiple cancer typesSmoker patientsGermline missense variantsNovel sequence variantsRisk factorsLeading causeR337H TP53 mutationLC pathogenesisSame patientLC casesPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply